Distribution of —844 G/A and Hind III C/G PAI-1 Polymorphisms and Plasma PAI-1 Levels in Mexican Subjects: Comparison of Frequencies Between Populations

Abstract

Several polymorphisms have been described in the PAI-1 gene including the —844 G/A and Hind III C/G polymorphisms. These polymorphisms have been associated with different diseases such as preeclampsia and cardiovascular diseases. The allele and genotype frequencies of both PAI-1 polymorphism where investigated in Mexican subjects and compared with other healthy worldwide populations. The hematological and biochemical parameters where classified according each genotype in our studied group. One hundred Mexican subjects were recruited. Demographic data and hematological and biochemical parameters were collected, and genomic DNA isolation was performed in all the participants. Screening of both polymorphisms studied was made by polymerase chain reaction and restriction analysis. Levels of plasminogen activator inhibitor-1 in plasma were measured by ELIS-ARA plasminogen activator inhibitor antigen kit. The —844 and Hind III genotypes frequencies were as follows: 49% (G/G), 40% (G/A), 11% (A/A) and 50% (C/C), 44% (C/G), 6% (G/G), respectively. The wild-type genotypes (G/G and C/C) were significantly higher with respect to the compared populations. In addition, a significant increase of apolipoprotein A1 in the carriers of G/A —844 and C/G Hind III genotypes was observed. However, when the plasma plasminogen activator inhibitor levels were analyzed with respect to each genotype and haplotype, no significant differences were found.

Keywords

Plasminogen activator inhibitor 1 polymorphism Mexican subjects

References

Kohler HP , Grant PJ Plasminogen-activator inhibitor type 1 and coronary artery disease . N Engl J Med. 2000;342:1792-1801.

Binder BR , Christ G. , Gruber F. , et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci. 2002;17:56-61.

Cho SH , Ryu CH , Oh CK Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med. 2004;229:138-146.

Lijnen HR Pleiotropic functions of plasminogen activator inhibitor-1. Thromb Haemost. 2005;3:35-45.

Grubic N. , Stegnar M. , Peternel P. , et al. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis . Thromb Res. 1996;84:431-443.

Benza RL , Grenett H. , Li XN , et al. Gene polymorphisms for PAI-1 are associated with the angiographic extent of coronary artery disease. J Thromb Thrombolysis. 1998;5: 143-150.

Benza RL , Grenett HE , Bourge RC , et al. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease . Circulation. 1998;98:2248-2254.

Fabbro D. , D'Elia AV , Spizzo R. , et al. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest. 2003 ;56: 17-22.

Lopes C. , Dina C. , Durand E. , et al. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetología. 2003;46:1284-1290.

10.

Haselbauer A. , Haberbosch W. , Tillmanns H. , et al. The impact of the PAI-1 A(—844)G promoter polymorphism on the risk and extent of coronary heart disease. Thromb Haemost. 2002;88:697-698.

11.

Dawson S. , Hamsten A. , Wiman B. , et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183-190.

12.

Ruiz-Quezada S. , Vázquez-Del Mercado M. , Parra-Rojas I. , et al. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico: association with biochemical and hematological parameters . Ann Genet. 2004;47:155-162.

13.

Miller SA , Dykes DD , Pulesky HF A simple salting out procedure for extracting DNA from human nucleated cells . Nucleid Acid Res. 1988;16:1215-1219.

14.

Henry M. , Chomiki N. , Scarabin PY , et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI-1 activity and triglyceride levels in a healthy population . Arterioscler Thromb Vasc Biol. 1997;17:851-858.

15.

Grenett HE , Khan N. , Jiang W. , et al. Identification of the Hind III polymorphic site in the PAI-1 gene: analysis of the PAI-1 Hind III polymorphism by PCR. Genet Test. 2000;4:65-68.

16.

Gorodesky C. , Alaez C. , Vázquez-García MN , et al. The genetic structure of Mexican mestizos of different locations: Tracking back their origins through MHC genes, blood group systems and microsatellites. Hum Immunol 2001;62:979-991

17.

Henry M. , Tregouet DA , Alessi MC , et al. Metabolic determinants are much more important than genetic polymorphism in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol. 1998;18:84-91.

18.

Morange PE , Henry M. , Tregouet D. , et al. The A—844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol. 2000;20:1387-1391.

19.

Lu F. , Hong J. , Kening S. , et al. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Chin Med J. 2001 ;114:266-269.

20.

Nuño-Arana I. , Páez-Riberos LA , Sandoval-Ramírez L. , et al. High prevalence of 5G allele in Amerindian tribes and Mestizos from Mexico at 4G/5G PAI-1 gene promoter polymorphism. Thromb Haemost. 2005;93:1005-1007.